Associate Professor at Ferrara University (2018-2020)
Appointed Full professor at Bologna University (2023)
Professional assignments
Medical Doctor (1983, with honours) - University of Ferrara- Italy
Postgraduate degree in Hematology- University of Ferrara (1986, with honours)
Postgraduate degree in Oncology (University of Ancona) (1989, with honours)
1990: Fellowship at Cambridge University Hospital
1991-92 : Fellowship at Hammersmith Hospital, Royal Postgraduate Medical School- Dept Haematology- University Hospital- London (Prof. J.M.Goldman, Dpt Director: Prof Lucio Luzzato); autologous transplant cohordinator
1996-2009: Responsible of Stem Cell Transplant Unit (CIC 330- EBMT), Stem Cell Biology and Flow Cytometry laboratory Labs at Ferrara University- Hospital- I
2002-03: Consultant at the International Cancer Centre in Rovigo- Italy (Prof Croce : scientific chair)
August 2009- June 2016 : Chief of the Hematology and Stem Cell Transplantation Unit (CIC 226-EBMT) Cremona Hospital- Cremona- Italy
June 2016- Today: Chief of the Hematology and Stem Cell Transplantation Unit at Ravenna Hospital (CIC 306)- Ravenna- Italy; Director of the Romagna Transplant Network for stem cell transplantation (including 3 clinical Unit in 3 different cities, 3 collection facilities and a Stem Cell Lab processing) (EBMT : CIC 306- 1-2-3);
2018: Associate Professor at Ferrara University (Hematology- Oncology)
2023: Full Professor Bologna University- Medical School of Ravenna
Selected Advisory Boards and Committees
- SubCommittee chair of the Acute Leukemia Working Party of the European Transplantation Society EBMT (auto transplant and graft composition) (2018-today)
- President of the Italian Society for Apheresis and Manipulation for Cellular Therapy (GIIMA) (2018-2021; 2021- 24)
- Chairman of the “Solid Tumor Working Party” of European Blood and Marrow Transplantation Society (2014-2017)Past President of the European branch of the International Society for Cell therapy (ISCT) : May 2008-May 2012. Web Site Member of CAT (Committee for Advanced Therapy) at EMA (European Medical Agency) (2010 2012)
- Past President of the Italian Society of Cytometry GIC (Society constituted of 1,000 members)- 2008-2012: web site: http://biotec.casaccia.enea.it/GIC/Direzione.html
- Associate Editor for Cytometry part B (Chicago, US, 2007- present): http://www3.interscience.wiley.com/journal/102019902/home/EditorialBoard.html
- Senior Editor of Transfusion and Apheresis Science Journal (US) 2018-today
- He acted as National expert for the European Commission (Research Directorate) (2005-2010) – Bruxelles
- He served as an independent expert with the evaluation of Specific Targeted Projects, Coordination Actions and Specific Support Actions proposals submitted to scientific support to policies in the framework of the “Integrating and Strengthening the European Research Area” (sixth framework programme) (March 2004 and June 2006) and 7th framework programme dealing with regenerative medicine.
- Past Chairman of the del “Quality Assessment of Stem cell Graft Committee” of the European Blood and Marrow Transplantation Society dal 2005 al 2012. web page: http://www.ebmt.org/7Directory/committees/qahscg.htm
- Member of the Standardization Committee on Clinical Flow Cytometry of the International Federation of Clinical Chemistry
- Committee member of the graft evaluation committee of WBMT –WHO affiliated working group
- Committee member of AHCTA (accreditation and Harmonisation Committee) of WBMT –WHO affiliated working group
- European Consortium on Stem Cell Mobilisation (ECOSM) (2010-2015)
- Member of Advanced Therapy Committee – European Medical Agency – EMA/EMEA (2010-2012)
- Chair of Scientific Secreteriat – Ethical Committee South Lobardia (2013-2016
Clinical Trial Cohordinator (profit and non profit)
1) “Quality Assessment of Autologous Blood Progenitor and Stem Cell Grafting. A prospective registration study ”. (QA01 Study) EBMT (European Blood and Marrow Transplantation Society ) 2010-2014 (patients accrual : 420 patients )
2) A phase II randomized, open-label neo-adjuvant study of standard chemotherapy regimen compared to high dose chemotherapy regimen with autologous stem cell transplantation in patients with triple negative breast cancer” 2013 Eudract N 2013-001226-25
3) Factors affecting successful mobilization with plerixafor: an Italian prospective study in patients with multiple myeloma and lymphoma undergoing autologous transplantation (GITMO study) (patients accrual : 250 patients )
4) Use of biosimilar G-CSF in patients with hematological malignancies undergoing autologous transplantation : an Italian prospective study (patients accrual : 250 patients )
5) Prospective study based on the use of Lonquex® (Lipegfilgrastim) for the prophylactc management chemotherapy-induced neutropenia (CIN) in patients with haematological malignancies. Patient accrual 250) – profit- Teva Farmaceutici.
6) Randomized, double blind, active controlled phase 3 study evaluating the efficacy and safety of ABP 959 compared with ECULIZUMAB in adult subjects with Paroxysmal nocturnal Hemoglobinuria (PNH) (2017) – studio profit Amgen
7) Biological study trial : “Progetto di studio di Area Vasta Romagna per lo screening di cloni EPN in pazienti con citopenia di diversa natura (idiopatica, in corso di anemia ipo-plastica o di mielodisplasia a basso grado IPSS), o associata a trombosi venosa idiopatica atipica o citopenia con segni di emolisi intravascolare: studio di validazione di un test rapido in citometria a flusso 3 colori
8) “Flow cytometry and NGS ASSESSMENT OF PNH CLONES IN CHRONIC Ph-NEG MYELOPROLIFERATIVE DISORDERS: A MULTICENTER TRIAL”: MyeloPNH : (Ravenna, Rimini, Meldola IRST, Padova, Vicenza, Udine, Verona, Siena)
9) Inotuzumab as a bridge to allogeneic stem cell transplant in patients with either refractory/relapsed or MRD-positive Acute Lymphoblastic Leukemia. A Study from the Acute Leukemia Working Party of the European society for Blood and Marrow Transplantation (EBMT).
10) CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A study from the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT)
11) A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
12) Fase III dello studio randomizzato, in doppio cieco, controllato con placebo sull’efficacia dell’aggiunta di crenolanib alla chemioterapia di salvataggio contro la chemioterapia di salvataggio da sola in soggetti ≤ 75 anni di età affetti da leucemia mieloide acuta recidivante/refrattaria con FLT3 mutato- Arog
13) A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
14) A Phase 3, Double-Blind, placebo controlled Study of Quizartinib (AC220) administered in combination with induction and consolidation chemotherapy , and administered as maintenance therapy in subjects 18 to 75 Years Old with newly diagnosed FLT3-ITD (+) Acute Myeloid Leukemia
15) A Phase 1, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome
16) A Phase 1/2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination with Azacitidine or Cytarabine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation
17) A Phase 1/2A First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia
18) A Phase 3, randomized, placebo-controlled study of the SYK inhibitor,entospletinib, in combination with standard induction and consolidation chemotherapy in newly diagnosed, NPM1-mutated Acute Myelogenous Leukemia
19) A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
20) Newly Diagnosed Adult Philadelphia Chromosome- Positive Acute Lymphoblastic Leukemia (Ph+ ALL). Sequential Treatment with Ponatinib and the Bispecific Monoclonal Antibody Blinatumomab vs Chemotherapy and Imatinib. Gimema No profit
21) A safety Run-in and phase 2-open label, multicentre study investigating safety tolerability and effectiveenss of venetoclax add in combination at fludarabibne cytarabine and idarubicine in induction therapy of new onset non M3 acute myeloid leukemia.
22) A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study evaluating the efficacy and safety of Crovalimab versus Eculizumab in adult and adolescent patients with Paroxysmal Nocturnal Hemoglobinuria not previously treated with complement inhibitors
23) A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study evaluating the efficacy and safety of Crovalimab versus Eculizumab in adult and adolescent patients with Paroxismal Nocturnal Hemoglobinuria (PNH) currently treated with complement inhibitors
24) A Randomized, Open-Label, Multicenter, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral BCX9930 Monotherapy for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in Subjects with Inadequate Response to C5 Inhibitor Therapy
25) Rischio Tromboembolico e Mortalità in Pazienti affetti da Malattia da agglutinine fredde (Cold Agglutinin Disease- CAD) in Italia.
Research activity
Hematopoietic Stem cells (HSC), autologous HSC transplantation, HSC manipulation, leukemia immunophenotyping, detection of minimal residual disease by flow cytometry, management of acute leukemia. Management of Clinical trials
He is author of > 270 original papers in international Journals (H index 41; IF > 1200) , 28 review articles or editorials, editor for 15 books (English text), 75 chapters from books, and 98 Italian papers.
Dr Lanza was invited speaker in > 530 International/Italian meeting/ courses.
Academical Degrees & Teaching activities.
